India’s commitment to enhance domestic pharmaceutical manufacturing and decrease reliance on imported drug intermediates has received a significant boost with the recent foundation stone laying for a multinational pharmaceutical manufacturing facility in the Kathua district of Jammu & Kashmir.
The facility, being developed by Orchid Pharma with support from the Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology, represents an investment of ₹600–700 crore and is strategically located at Village Gadadhar in Kathua district.
The foundation stone was laid by the Union Minister of State (Independent Charge) for Science & Technology and Earth Sciences, Dr. Jitendra Singh. This initiative marks a considerable step towards bolstering India’s pharmaceutical independence.
Strengthening India’s Pharmaceutical Landscape
In his address, Dr. Jitendra Singh highlighted that this investment underscores the growing confidence of the industry in the industrial and innovation capabilities of Jammu & Kashmir. The project is being developed under the Government of India’s Production Linked Incentive (PLI) Scheme, which aims to stimulate domestic manufacturing in vital sectors.
The facility is anticipated to generate around 400 direct jobs alongside approximately 400 additional indirect employment opportunities across logistics, supply chains, services, and ancillary industries.
Dr. Singh noted that Kathua, with its expanding industrial infrastructure, holds the potential to become a prominent pharmaceutical manufacturing hub in northern India, thus contributing significantly to the country’s pharmaceutical exports.
Domestic Production of Critical Antibiotic Intermediate
The upcoming facility will produce Amino Cephalosporanic Acid (ACA), a crucial pharmaceutical intermediate used in the manufacture of cephalosporin antibiotics, which are essential for treating bacterial infections. Currently, India relies heavily on imports from China for this vital intermediate, which poses risks to supply security and pricing.
Dr. Singh stated that the new manufacturing unit will markedly reduce India’s dependence on imports and fortify domestic pharmaceutical supply chains. He remarked, “Antibiotics are foundational to modern healthcare, and the pandemic highlighted the vulnerabilities associated with reliance on a single geography for essential inputs.”
Advancing India’s Global Pharmaceutical Leadership
The Minister articulated that this project aligns with the broader vision of Prime Minister Narendra Modi to foster self-reliance in critical healthcare technologies and pharmaceutical manufacturing. He also pointed to the recently announced ₹10,000 crore ‘Biopharma Shakti’ initiative introduced in the Union Budget, aimed at further enhancing India’s biotechnology and biopharmaceutical ecosystem.
India is emerging as a significant player in the global biotechnology industry, currently ranking third in biomanufacturing in the Asia-Pacific region and 30th worldwide, with considerable growth potential in advanced pharmaceutical manufacturing. Dr. Singh asserted that the establishment of such advanced pharmaceutical manufacturing units could position Kathua prominently on India’s pharmaceutical export map.
Integrating Jammu & Kashmir into the National Economy
Dr. Jitendra Singh articulated that the Kathua facility signifies a new developmental approach for Jammu & Kashmir, concentrating on innovation-led industrialisation, skill development, and long-term value creation. He emphasised that such investments will aid in integrating the region into India’s national economic growth narrative, particularly in high-value sectors like biotechnology and pharmaceuticals.
He remarked, “This is not merely about reducing imports; it is about building strategic capability where it matters most.” Strengthening domestic pharmaceutical production will also enhance India’s health security, ensuring the availability and affordability of essential medicines, even during global supply disruptions.
The Future of Biotechnology in India
Dr. Rajesh Gokhale, Secretary of the Department of Biotechnology, stated that India’s bioeconomy is becoming a fundamental pillar of the country’s scientific and economic development. He noted that initiatives such as the Kathua project exemplify how science-led biomanufacturing can position India as a global competitor in biotechnology and advanced pharmaceutical production.
Collaboration with Global Pharma Leader
The manufacturing facility is being developed by Orchid Bio Pharma, recognised as one of the world’s leading manufacturers of cephalosporin antibiotics. The company operates in over 60 countries and serves more than 200 global clients through international partnerships, rendering the Kathua project strategically vital for India’s pharmaceutical export ambitions.
The foundation stone ceremony was attended by various senior government and industry leaders, including Dr. Jitendra Kumar, Managing Director of BIRAC; Shri Ram Gopal Agarwal, Chairman of Dhanuka Group; Shri Manish Dhanuka, Managing Director of Orchid Biopharma; and Shri Rajesh Sharma, Deputy Commissioner of Kathua.
The Kathua facility is poised to significantly enhance India’s pharmaceutical manufacturing capacity, mitigate reliance on imported drug intermediates, and position the region as a burgeoning centre for biotechnology and pharmaceutical innovation.